An Israeli startup Neurolief has developed a breaking through home treatment for migraine, depression as well as a range of neurological and neuropsychiatric disorders.
The European Medicines Authority has approved the marketing of Relivion, a ligament attached to the forehead and relieves the pain by sending electrical signals to the brain.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Migraine is described as a “moderately severe” headache, usually on one side of the head, which worsens during exercise and exposure to light, sounds or smells, and is sometimes combined with nausea and vomiting.
Migraine episode can last for a long time, every day or once every few weeks, months or even years.
Although migraines can attack at any age, they are common in the 10-40 age group. In most people the migraine attacks cyclically and its intensity decreases towards age 50.
Migraine is three times more common in women and tends to be hereditary: More than half of migraine sufferers report relatives who have the same problem.
The medical literature describes dozens of causes of migraine attacks, including consumption of caffeine-containing beverages and foods, minority or excessive hours of sleep, eating yellow cheese, alcohol consumption and temperature changes.
The Netanya-based company “Neurolief” founded in 2014, by Amit Dar and Shmuel Shany. Both Dar and Shany were among the founders of NESS, the developer of devices that provide mild electrical neuromuscular stimulation to help stroke survivors move paralyzed arms and legs.
The Migraine market today dominated by large companies offering implant of a device in the brain and involve invasive surgery to treat headaches.
Amit Dar told Globes some 50%-60% of the patients with implanted device require additional surgery, either because the electrodes have shifted or due to infection and inflammation around the implant.
Neurolief offers an effective treatment without the risks and costs associated with invasive procedures and without the side effects associated with medications. Patients can start using it in minutes and use it only at the time the pains started.
The new device is a strip attached to the scalp, which transmits electric currents signals to six sections in the brain of the occipital nerve passing through the hindbrain, and the trigeminal nerve that passes through the front of the face.
The signals sent from the ligament through an app, irritate nerves in the brain, thus creating “neuromodulation,” which blocks the nerve signals that cause the pain. Through the app, the patient directs the desired treatment. Over time, the system “learns” the optimal treatment that helps the patient.
This is the first “neuromodulation” technology that enables efficient and safe home treatment.
Neurolief support by Terralab Ventures Incubator, Terra Venture Partners, the franchisers of Terralab incubator and American investors.
